FrankStephenHodiJr.MD

Clinical Trials

• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer Start of enrollment: 2002 Mar 01

  Terminated

  Phase 1

• Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma Start of enrollment: 2002 Sep 01

  Completed

  Not Applicable

• Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01

  Unknown status

  Phase 2

• Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma Start of enrollment: 2005 Jan 01

  Completed

  Phase 1

• Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma Start of enrollment: 2006 Jul 01

  Completed

  Phase 2

• SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Start of enrollment: 2007 Aug 01

  Completed

  Phase 2

• In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer Start of enrollment: 2008 Feb 01

  Completed

  Phase 1

• Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23

  Completed

  Phase 2

• Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma Start of enrollment: 2009 Feb 26

  Completed

  Phase 1

• Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Stimulating Factor (GMSF) Start of enrollment: 2003 Oct 16

  Active, not recruiting

  Phase 1

• Dinaciclib in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2009 Sep 01

  Terminated

  Phase 1, Phase 2

• Panobinostat (LBH589) in Patients With Metastatic Melanoma Start of enrollment: 2010 Feb 01

  Completed

  Phase 1

• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2010 Dec 28

  Active, not recruiting

  Phase 2

• STA-9090(Ganetespib) in Metastatic Ocular Melanoma Start of enrollment: 2010 Sep 17

  Completed

  Phase 2

• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25

  Active, not recruiting

  Phase 3

• STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2011 Sep 01

  Terminated

  Phase 2

• Dendritic Cell Activating Scaffold in Melanoma Start of enrollment: 2013 Jun 01

  Active, not recruiting

  Phase 1

• Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) Start of enrollment: 2013 Apr 30

  Completed

  Phase 2

• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24

  Active, not recruiting

  Phase 2

• Join now to see all